Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
We describe the use of pretargeted radioimmunotherapy (PRIT) using an anti-murine CD45 antibody-streptavidin (SA) conjugate followed by radiobiotin to deliver radiation selectively to murine hematolymphoid tissues, which may potentially augment the efficacy and decrease the toxicity of radioimmunotherapy for disseminated murine leukemia. Biodistribution and therapeutic results demonstrated high target organ to nontarget organ ratios of radioactivity and significant long-term survival in leukemic mice using PRIT. These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies.
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. jpagel@fhcrc.org
John M
JM
Pagel
Nathan
N
Hedin
Lacey
L
Drouet
Brent L
BL
Wood
Anastasia
A
Pantelias
Yukang
Y
Lin
Donald K
DK
Hamlin
D Scott
DS
Wilbur
Ajay K
AK
Gopal
Damian
D
Green
Frederick R
FR
Appelbaum
Oliver W
OW
Press
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000532:radiotherapy*; D017493:Leukocyte Common Antigens / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D016499:Radioimmunotherapy / Q000379:methods*
D007457:Iodine Radioisotopes; D017493:Leukocyte Common Antigens